Nao Hiwatashi1, Shigeyuki Mukudai1, Renjie Bing1, Ryan C Branski1. 1. Department of Otolaryngology-Head and Neck Surgery, New York University Voice Center, New York University School of Medicine, New York, New York, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: Our laboratory recently described NR4A1 as an endogenous inhibitor of TGF-β-induced vocal fold (VF) fibrosis. Our prior report described the temporal expression of NR4A1 during VF healing in vivo and the effects of NR4A1 knockdown on fibroplastic cell activities in vitro. Based on these findings, we hypothesized that cytosporone-B (Csn-B), an NR4A1 agonist, may hold significant therapeutic potential. STUDY DESIGN: In vitro. METHODS: Human VF fibroblasts were exposed to TGF-β1+/-Csn-B. Expression of genes related to fibrosis were quantified. In addition, contraction was assayed as a surrogate for the fibrotic phenotype in our cell line. RESULTS: TGF-B1 stimulated COL1A1 and ACTA2, as expected. Csn-B significantly downregulated TGF-β1-mediated upregulation of these genes (P = .009, P = .03, respectively). Csn-B had no effect on genes related to TGF-β/Smad signaling. Csn-B also decreased the TGF-β1-mediated contractile phenotype in our cells (P = .004). CONCLUSIONS: NR4A1 is an endogenous inhibitor of fibrosis in the vocal folds and Csn-B, as an NR4A1 agonist, may evolve as an ideal, therapeutic candidate for this challenging condition. LEVEL OF EVIDENCE: NA Laryngoscope, 128:E425-E428, 2018.
OBJECTIVES/HYPOTHESIS: Our laboratory recently described NR4A1 as an endogenous inhibitor of TGF-β-induced vocal fold (VF) fibrosis. Our prior report described the temporal expression of NR4A1 during VF healing in vivo and the effects of NR4A1 knockdown on fibroplastic cell activities in vitro. Based on these findings, we hypothesized that cytosporone-B (Csn-B), an NR4A1 agonist, may hold significant therapeutic potential. STUDY DESIGN: In vitro. METHODS:HumanVF fibroblasts were exposed to TGF-β1+/-Csn-B. Expression of genes related to fibrosis were quantified. In addition, contraction was assayed as a surrogate for the fibrotic phenotype in our cell line. RESULTS:TGF-B1 stimulated COL1A1 and ACTA2, as expected. Csn-B significantly downregulated TGF-β1-mediated upregulation of these genes (P = .009, P = .03, respectively). Csn-B had no effect on genes related to TGF-β/Smad signaling. Csn-B also decreased the TGF-β1-mediated contractile phenotype in our cells (P = .004). CONCLUSIONS:NR4A1 is an endogenous inhibitor of fibrosis in the vocal folds and Csn-B, as an NR4A1 agonist, may evolve as an ideal, therapeutic candidate for this challenging condition. LEVEL OF EVIDENCE: NA Laryngoscope, 128:E425-E428, 2018.
Authors: Nao Hiwatashi; Peter A Benedict; Gregory R Dion; Renjie Bing; Iv Kraja; Milan R Amin; Ryan C Branski Journal: Laryngoscope Date: 2017-05-20 Impact factor: 3.325
Authors: Stephen Safe; Un-Ho Jin; Benjamin Morpurgo; Ala Abudayyeh; Mandip Singh; Ronald B Tjalkens Journal: J Steroid Biochem Mol Biol Date: 2015-04-23 Impact factor: 4.292
Authors: Ryan C Branski; Silvia S Barbieri; Babette B Weksler; Benjamin Saltman; Priya Krishna; Dennis H Kraus; Nalini V Broadbelt; Jie Chen; Dix P Poppas; Diane Felsen Journal: Ann Otol Rhinol Laryngol Date: 2009-03 Impact factor: 1.547
Authors: Aron Parekh; Vlad C Sandulache; Audrey S Lieb; Joseph E Dohar; Patricia A Hebda Journal: Wound Repair Regen Date: 2007 May-Jun Impact factor: 3.617
Authors: Camilo Mora-Navarro; Andreea Badileanu; Ana M Gracioso Martins; Emily W Ozpinar; Lewis Gaffney; Ian Huntress; Erin Harrell; Jeffrey R Enders; Xinxia Peng; Ryan C Branski; Donald O Freytes Journal: ACS Biomater Sci Eng Date: 2020-02-11